Naomi B. Klarenbeek

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Phase I trial in participants with rheumatoid arthritis and healthy volunteers with CIT-013, a first-in-class extracellular traps targeted therapy.

Phase I trial in participants with rheumatoid arthritis and healthy volunteers with CIT-013, a first-in-class extracellular traps targeted therapy.

Journal: EULAR rheumatology open

Published: August 01, 2026

Intravaginal Delivery of Oxybutynin: An Alternative Administration Route to Improve its Pharmacokinetic and Pharmacodynamic Effects.

Intravaginal Delivery of Oxybutynin: An Alternative Administration Route to Improve its Pharmacokinetic and Pharmacodynamic Effects.

Journal: European urology open science

Published: July 09, 2026

Lost and found in translation: the value of the human imiquimod model.

Lost and found in translation: the value of the human imiquimod model.

Journal: British journal of clinical pharmacology

Published: April 02, 2026

Interpretation of Chemistry, Hematology and Coagulation Laboratory Results in Early-Phase Clinical Pharmacology Trials; a Retrospective Analysis Based on the Placebo Arm of Randomized-Controlled Trials.

Interpretation of Chemistry, Hematology and Coagulation Laboratory Results in Early-Phase Clinical Pharmacology Trials; a Retrospective Analysis Based on the Placebo Arm of Randomized-Controlled Trials.

Journal: Clinical and translational science

Published: February 09, 2026

Introducing personalized patient care in overactive bladder management using the MedRing OAB system for intravaginal oxybutynin administration.

Introducing personalized patient care in overactive bladder management using the MedRing OAB system for intravaginal oxybutynin administration.

Journal: Drug delivery

Published: January 24, 2026

First-in-human (phase I) trial of SOL-116, a humanised IgG4 monoclonal antibody targeting bile salt-stimulated lipase, in healthy participants and rheumatoid arthritis patients.

First-in-human (phase I) trial of SOL-116, a humanised IgG4 monoclonal antibody targeting bile salt-stimulated lipase, in healthy participants and rheumatoid arthritis patients.

Journal: RMD open

Published: January 09, 2026

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double-blind randomized clinical trial in patients with mild to moderate atopic dermatitis.

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double-blind randomized clinical trial in patients with mild to moderate atopic dermatitis.

Journal: British journal of clinical pharmacology

Published: November 07, 2025

Early immune responses to intradermal lipopolysaccharide in healthy volunteers: prednisolone's impact on TLR4-mediated inflammation.

Early immune responses to intradermal lipopolysaccharide in healthy volunteers: prednisolone's impact on TLR4-mediated inflammation.

Journal: Frontiers in immunology

Published: October 14, 2025

POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following in vivo LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled study.

POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following in vivo LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled study.

Journal: Frontiers in immunology

Published: August 12, 2025

Breaking Barriers: Characterization of the Intradermal Lipopolysaccharide Challenge as an In Vivo Model for Controlled Induction of Vascular Leakage in Healthy Volunteers.

Breaking Barriers: Characterization of the Intradermal Lipopolysaccharide Challenge as an In Vivo Model for Controlled Induction of Vascular Leakage in Healthy Volunteers.

Journal: Clinical pharmacology and therapeutics

Published: August 06, 2025

Clinical Validation of Imaging Biomarkers in Mycosis Fungoides.

Clinical Validation of Imaging Biomarkers in Mycosis Fungoides.

Journal: Experimental dermatology

Published: July 01, 2025

Pharmacokinetics, safety, tolerability and fluorescence imaging of nizaracianine triflutate administered in three divided doses to healthy volunteers.

Pharmacokinetics, safety, tolerability and fluorescence imaging of nizaracianine triflutate administered in three divided doses to healthy volunteers.

Journal: British journal of clinical pharmacology

Published: April 30, 2025

Showing 1-12 of 35

Last Updated: 09/26/2026